Tags

Type your tag names separated by a space and hit enter

The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis.
J Ophthalmol. 2014; 2014:317694.JO

Abstract

Purpose.

Ischemic central retinal vein occlusion (CRVO) eyes are at high risk of developing neovascular glaucoma (NVG). Our purpose is to investigate the effect of anti-VEGF therapy for macular edema after CRVO on the development of neovascular glaucoma (NVG) in ischemic CRVO eyes. Methods. This is a retrospective case series of 44 eyes from 44 patients with CRVO treated with anti-VEGF therapy for macular edema. The primary outcome was the development of NVG.

Results.

Of the 44 eyes, 14 eyes had ischemic CRVO, and 30 eyes had nonischemic CRVO. Nonischemic eyes received a mean of 8.4 anti-VEGF doses, over mean follow-up of 24 months. One nonischemic eye (3.3%) developed NVD but not NVG. The 14 ischemic eyes received a mean of 5.6 anti-VEGF doses, with mean follow-up of 23 months. Of these 14 ischemic eyes, two eyes (14%) developed iris neovascularization and 3 eyes (21%) developed posterior neovascularization. Three of these 5 eyes with neovascularization progressed to NVG, at 19.7 months after symptom onset, on average.

Conclusion.

Anti-VEGF therapy for macular edema may delay, but does not prevent, the development of ocular NV in ischemic CRVO. Significant risk of NVG still exists for ischemic CRVO eyes.

Authors+Show Affiliations

Department of Ophthalmology, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA.Department of Ophthalmology, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA.Department of Ophthalmology, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA.Department of Ophthalmology, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA.Department of Ophthalmology, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA.Department of Ophthalmology, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA ; Department of Ophthalmology, Henry Ford Medical Center, 6530 Farmington Road, West Bloomfield, MI 48322, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24800060

Citation

Ryu, Christina L., et al. "The Effect of Antivascular Endothelial Growth Factor Therapy On the Development of Neovascular Glaucoma After Central Retinal Vein Occlusion: a Retrospective Analysis." Journal of Ophthalmology, vol. 2014, 2014, p. 317694.
Ryu CL, Elfersy A, Desai U, et al. The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis. J Ophthalmol. 2014;2014:317694.
Ryu, C. L., Elfersy, A., Desai, U., Hessburg, T., Edwards, P., & Gao, H. (2014). The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis. Journal of Ophthalmology, 2014, 317694. https://doi.org/10.1155/2014/317694
Ryu CL, et al. The Effect of Antivascular Endothelial Growth Factor Therapy On the Development of Neovascular Glaucoma After Central Retinal Vein Occlusion: a Retrospective Analysis. J Ophthalmol. 2014;2014:317694. PubMed PMID: 24800060.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis. AU - Ryu,Christina L, AU - Elfersy,Adrian, AU - Desai,Uday, AU - Hessburg,Thomas, AU - Edwards,Paul, AU - Gao,Hua, Y1 - 2014/04/01/ PY - 2013/12/22/received PY - 2014/02/26/revised PY - 2014/03/04/accepted PY - 2014/5/7/entrez PY - 2014/5/7/pubmed PY - 2014/5/7/medline SP - 317694 EP - 317694 JF - Journal of ophthalmology JO - J Ophthalmol VL - 2014 N2 - Purpose. Ischemic central retinal vein occlusion (CRVO) eyes are at high risk of developing neovascular glaucoma (NVG). Our purpose is to investigate the effect of anti-VEGF therapy for macular edema after CRVO on the development of neovascular glaucoma (NVG) in ischemic CRVO eyes. Methods. This is a retrospective case series of 44 eyes from 44 patients with CRVO treated with anti-VEGF therapy for macular edema. The primary outcome was the development of NVG. Results. Of the 44 eyes, 14 eyes had ischemic CRVO, and 30 eyes had nonischemic CRVO. Nonischemic eyes received a mean of 8.4 anti-VEGF doses, over mean follow-up of 24 months. One nonischemic eye (3.3%) developed NVD but not NVG. The 14 ischemic eyes received a mean of 5.6 anti-VEGF doses, with mean follow-up of 23 months. Of these 14 ischemic eyes, two eyes (14%) developed iris neovascularization and 3 eyes (21%) developed posterior neovascularization. Three of these 5 eyes with neovascularization progressed to NVG, at 19.7 months after symptom onset, on average. Conclusion. Anti-VEGF therapy for macular edema may delay, but does not prevent, the development of ocular NV in ischemic CRVO. Significant risk of NVG still exists for ischemic CRVO eyes. SN - 2090-004X UR - https://www.unboundmedicine.com/medline/citation/24800060/The_effect_of_antivascular_endothelial_growth_factor_therapy_on_the_development_of_neovascular_glaucoma_after_central_retinal_vein_occlusion:_a_retrospective_analysis_ L2 - https://doi.org/10.1155/2014/317694 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.